Clinical Trials Logo

Neoplasms, Squamous Cell clinical trials

View clinical trials related to Neoplasms, Squamous Cell.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06333665 Active, not recruiting - Surgery Clinical Trials

PPIO-007 Correlation Analysis of Type II Diabetes Mellitus on Short-term and Long-term Outcomes of Patients With Esophageal Squamous Cell Cancer Undergoing Minimally Invasive Esophagectomy

Start date: February 20, 2024
Phase:
Study type: Observational

To date, there is controversy as to whether type II diabetes mellitus is associated with adverse short- and long-term outcomes in patients with esophageal squamous cell carcinoma undergoing minimally invasive esophagectomy. At the same time, to the best of our knowledge, the impact of metformin use and glycemic control on short- and long-term outcomes in this patient population is also controversial. Therefore, this study aims to test the hypothesis that diabetes mellitus is associated with reduced survival in patients with esophageal squamous cell carcinoma undergoing minimally invasive esophagectomy and that treatment with metformin and/or good glycemic control (HbA1c<7.0%) is associated with improved survival.

NCT ID: NCT06061263 Active, not recruiting - Esophageal Cancer Clinical Trials

Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant Chemoradiotherapy

Start date: May 1, 2022
Phase:
Study type: Observational

It has been reported that patients with esophageal squamous cell carcinoma who achieved pathological complete response (PCR) to neoadjuvant chemoradiotherapy have better survival than those with non-PCR. Howeve, there is still recurrent diseases developed in PCR patients after esophagectomy. Herein, we aimed to investgate the risk factors of recurrence in PCR patients.

NCT ID: NCT04504669 Active, not recruiting - Melanoma Clinical Trials

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Start date: August 18, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors

NCT ID: NCT04116320 Active, not recruiting - Breast Cancer Clinical Trials

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

AM-003
Start date: November 21, 2019
Phase: Phase 1
Study type: Interventional

This study evaluates whether it is safe to Focused Ultrasound Ablation (FUSA) treatments with and without PD-1 blockade and with and without intratumoral poly-ICLC. A device called the Echopulse will be used for the FUSA therapy. Patients will be assigned to 1 of 2 cohorts depending on their disease and treatment status. In Cohort 1, patients will receive FUSA therapy while receiving PD-1 blockade therapy as part of standard clinical care treatment. In Cohort 2, patients who discontinue or are ineligible for PD-1 blockade therapy will undergo FUSA without concurrent systemic therapy, with the goal of utilizing the FUSA to boost the innate immune response. The optional secondary regimen will combine FUSA (+/- PD-1 blockade) with intratumoral poly-ICLC.

NCT ID: NCT03712566 Active, not recruiting - Cancer Clinical Trials

Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy

MASST
Start date: November 6, 2018
Phase:
Study type: Observational

This is prospective research study which will include patients with recurrent or metastatic squamous cell carcinoma of the head and neck, esophagus and anal canal starting on first-line platinum based chemotherapy or any line of immunotherapy treatment.This study aims to characterize the dynamic changes in genomic, epigenetic, immune profiling and imaging data during treatment with systemic therapy. Patients will have archived tumor samples requested as well as blood samples collected at up to four time points to analyze these changes. Imaging data will be derived from patients' routine CT scans before and after treatment.

NCT ID: NCT03667482 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Cancer

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Start date: September 7, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of cabozantinib, at different doses, in combination with cetuximab to find out what effects, if any, this combined treatment has on people with HNSCC.

NCT ID: NCT03521570 Active, not recruiting - Clinical trials for Recurrent Head and Neck Squamous Cell Carcinoma

Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer

Start date: June 28, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well intensity-modulated radiotherapy and nivolumab work together in treating patients with head and neck squamous cell cancer that has come back. Intensity-modulation radiation therapy uses varying intensities of radiation beams to kill cancer cells and shrink tumors, thereby reducing the damage to nearby healthy tissue. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving intensity-modulated radiation therapy and nivolumab may work better at treating head and neck squamous cell cancer.

NCT ID: NCT03370276 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Start date: December 20, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find out if the combination of two established anti-cancer therapies are beneficial in participants with Head and Neck Squamous Cell Carcinoma (HNSCC). Specifically, investigators want to determine if the combination of Cetuximab and nivolumab can help people with advanced cases of HNSCC. Both cetuximab and nivolumab have been used separately to treat HNSCC and are Food and Drug Administration (FDA) approved in this type of cancer.

NCT ID: NCT03336606 Active, not recruiting - Clinical trials for Head and Neck Cancer

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

Start date: July 25, 2018
Phase: Phase 1
Study type: Interventional

This clinical trial will evaluate the safety and feasibility of a humanized OX40 agonist, MEDI0562, in the pre-operative setting for patients with head and neck squamous cell carcinoma or melanoma.

NCT ID: NCT03138070 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Cancer

A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719

Start date: October 20, 2017
Phase: N/A
Study type: Interventional

Single centre, single arm, preoperative window of opportunity study with a biomarker endpoint (expression profiling by RNA sequencing). Patients with resectable, histologically confirmed head and neck squamous cell carcinoma (HNSCC) for whom surgical treatment is planned as definitive management will be eligible.